National and Kapodistrian University of Athens
Επίπεδα HBsAg ορού σε ασθενείς με HBeAg-αρνητική χρόνια ηπατίτιδα Β υπό μακροχρόνια αντιική θεραπεία
Abstract
dc:descriptionBackground/Aims: Serum HBsAg levels might be used as predictor of virological breakthrough or of sustained off-treatment virological response in HBeAg-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. Methods: We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11, telbivudine: 16) and 86 HBeAg-negative CHB patients under entecavir or tenofovir for a mean of 30 months as the comparison group. Results: Compared to baseline, HBsAg levels decreased by a median of 162, 1525, 943, 1545, 2163, 3859 IU/mL at 6, 12, 24, 36, 48 and 60 months of therapy with low-genetic barrier NA(s), respectively. The 6-, 12-, 24-, 36-, 48- and 60-month cumulative rates of HBsAg<100 IU/mL were 2%, 3%, 3%, 5%, 5% and 5% and <1000 IU/mL 6%, 9%, 15%, 19%, 24% and 61% respectively. Baseline HBsAg levels was the only significant variable associated with the time to HBsAg drop <1000 IU/mL. HBsAg loss occurred in 3.0%. The high-genetic barrier NAs were not found to offer a greater or faster HBsAg decline. Conclusions: In HBeAg-negative CHB patients, long-term therapy with low-genetic barrier NA(s) decreases serum HBsAg levels, but the rate of decline is slow. Lower baseline HBsAg levels are significantly associated with on-therapy HBsAg drop <1000 IU/mL. Serum HBsAg decline is similar during therapy with low- or high-genetic barrier NAs.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Striki, Athanasia
- Στρίκη, Αθανασία
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41324